Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.19.8469

Lack of Prognostic Significance of SOCS-1 Expression in Colorectal Adenocarcinomas  

Ayyildiz, Talat (Department of Gastroenterology, School of Medicine, Ondokuz Mayis University)
Dolar, Enver (Department of Gastroenterology, School of Medicine, Uludag University)
Adim, Saduman Balaban (Department of Pathology, School of Medicine, Uludag University)
Eminler, Ahmet Tarik (Department of Gastroenterology, School of Medicine, Uludag University)
Yerci, Omer (Department of Pathology, School of Medicine, Uludag University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.19, 2014 , pp. 8469-8474 More about this Journal
Abstract
Introduction: Recent studies have indicated that down-regulation of the suppressor of cytokine signaling-1 (SOCS-1) gene results in tumor formation and that SOCS-1 acts as a tumor suppressor gene. SOCS-1 has been also suggested to function as a tumor suppressor with colorectal cancer. Objectives: In the present study, we aimed to determine the association of SOCS-1 expression in colorectal cancer tissues with clinicopathologic characteristics immunohistochemically and also to identify its prognostic significance. Materials and Methods: SOCS-1 expression was studied immunohistochemically in 67 patients diagnosed with resected colorectal carcinomas and 30 control subjects. Results: SOCS-1 expression was found in 46.3% of tumor tissues and 46.7% of the control group. Statistical analyses did not establish any significant association between SOCS-1 expression and clinicopathologic characteristics. Also, no significant association with SOCS-1 expression was found using progression-free survival and overall survival analyses (p=0.326 and p=0.360, respectively). Conclusions: Our results show that SOCS-1 has no prognostic significance in colorectal cancer.
Keywords
Colorectal carcinoma; methylation; suppressor of cytokine signaling-1; tumour suppressor;
Citations & Related Records
Times Cited By KSCI : 5  (Citation Analysis)
연도 인용수 순위
1 Shima K, Morikawa T, Yamauchi M, et al (2011). TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers. PLoS One, 6, 25062.   DOI
2 Oshino Y, Kuraoka K, Nakayama H, et al (2004). Epigenetic inactiviation of SOCS-1 by CpG island hypermethylation in human gastric carsinoma. Int J Cancer, 112, 1003-9.   DOI
3 Rakesh K, Agrawal DK (2005). Controlling cytokine signaling by constitutive inhibitors. Biochem Pharmacol, 70, 649-57.   DOI
4 Rottapel R, Ilangumaran S, Neale C, et al (2002). The tumor suppressor activity of SOCS-1. Oncogene, 21, 4351-62.   DOI   ScienceOn
5 Siegel R, DeSantis C, Virgo K, et al (2012). Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin, 62, 220-41.   DOI
6 Siegel R,Ward E, Brawley O, Jemal A (2011). Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin, 61, 212-36.   DOI
7 Slattery ML, Lundgreen A, Kadlubar SA, Bondurant KL, Wolff RK (2011). JAK/STAT/SOCS-signaling pathway and colon and rectal cancer. Mol Carcinog, 52, 155-66.
8 Sutherland KD, Lindeman GJ, Choong DY, et al (2004). Differential hypermethylation of SOCS genes in ovarian and breast carsinomas. Oncogene, 23, 7726-33.   DOI   ScienceOn
9 To KF, Chan MW, Leung WK, et al (2004). Constitutional activation of IL-6-mediated JAK/STAT pathway through hypermethylation of SOCS-1 in human gastric cancer cell line. Br J Cancer, 91, 1335-41.   DOI
10 Toyota M, Issa JP (1999). CpG island methylator phenotypes in aging and cancer. Semin Cancer Biol, 9, 349-57.
11 Walsh JM, Terdiman JP (2003). Colorectal cancer screening: scientific review. JAMA, 289, 1288-96.   DOI   ScienceOn
12 Yang YF, Zhang XY, Yang M, et al (2014). Prognostic role of nucleophosmin in colorectal carcinomas. Asian Pac J Cancer Prev, 15, 2021-6.   DOI
13 Watanabe D, Ezoe S, Fujimoto M, et al (2004). Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines. Br J Haematol, 126, 726-35.   DOI
14 Wilkinson N, Scott-Conner CE (2008). Surgical therapy for colorectal adenocarcinoma. Gastroenterol Clin North Am, 37, 253-67.   DOI
15 Wolpin BM, Mayer RJ (2008). Systemic treatment of colorectal cancer. Gastroenterology, 134, 1296-310.   DOI   ScienceOn
16 Yoshikawa H, Matsubara K, Qian GS, et al (2001). SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet, 28, 29-35.
17 Yoshimura A, Nishinakamura H, Matsumura Y, Hanada T (2005). Negative regulation of cytokine signaling and immune responses by SOCS proteins. Arthritis Res Ther, 7, 100-10.   DOI
18 Zlobec I, Lugli A (2008). Prognostic and predictive factors in colorectal cancer. J Clin Pathol, 61, 561-69.
19 Ahuja N, Issa JP (2000). Aging, methylation and cancer. Histol Histopathol, 15, 835-42.
20 Abdel-Rahman WM, Nieminen TT, Shoman S, Eissa S, Peltomaki P (2014). Loss of p15INK4b expression in colorectal cancer is linked to ethnic origin. Asian Pac J Cancer Prev, 15, 2083-7.   DOI
21 Andre T, Boni C, Navarro M, et al (2009). Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol, 27, 3109-16.   DOI   ScienceOn
22 Chan AT, Baba Y, Shima K, et al (2010). Cathepsin B expression and survival in colon cancer: Implications for molecular detection of neoplasia. Cancer Epidemiol Biomark Prev, 19, 2777-85.   DOI
23 Boursi B, Arber N (2007). Current and future clinical strategies in colon cancer prevention and the emerging role of chemoprevention. Curr Pharm Des, 13, 2274-82.   DOI
24 Denlinger CS, Cohen SJ (2007). Progress in the development of prognostic and predictive markers for gastrointestinal malignancies. Curr Treat Options Oncol, 8, 339-51.   DOI
25 Chai SK, Nichols GL, Rothman P (1997). Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol, 159, 4720-28.
26 Colussi D, Brandi G, Bazzoli F, Ricciardiello L (2013). Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci, 14, 16365-85.   DOI
27 Dong H, Tang J, Li LH, et al (2013). Serum carbohydrate antigen 19-9 as an indicator of liver metastasis in colorectal carcinoma cases. Asian Pac J Cancer Prev, 14, 909-13.   DOI   ScienceOn
28 Fang WJ, Zheng Y, Wu LM, et al (2012). Genome-wide analysis of aberrant DNA methylation for identification of potential biomarkers in colorectal cancer patients. Asian Pac J Cancer Prev, 13, 1917-21.   DOI   ScienceOn
29 Farabegoli F, Ceccarelli C, Santini D, Taffurelli M (2005). Suppressor of cytokine signalling 2(SOCS-2) expression in breast carcinoma. J Clin Pathol, 58, 1046-50.   DOI
30 Firestein R, Shima K, Nosho K, et al (2010). CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival. Int J Cancer, 126, 2863-73.
31 Grady WM, Carethers JM (2008). Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterol, 135, 1079-99.   DOI   ScienceOn
32 Fujitake S, Hibi K, Okochi O, et al (2004). Aberrant methylation of SOCS-1 was observed in younger colorectal cancer patients. J Gastroenterol, 39, 120-4.   DOI
33 He B, You L, Xu Z, et al (2003). SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth inhuman lung cancer. Proc Natl Acad Sci USA, 100, 14133-8.   DOI
34 Fukushima N, Sato N, Sahin F, et al (2003). Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms. Br J Cancer, 89, 338-43.   DOI
35 Hanada T, Kobayashi T, Chinen T, et al (2006). IFN gamma dependent, spontaneous development of colorectal carcinomas in SOCS-1-deficient mice. J Exp Med, 203, 1391-7.   DOI   ScienceOn
36 Imamura Y, Morikawa T, Liao X, et al (2012). Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res, 18, 4753-63.   DOI
37 Issa JP (2008). Colon cancer: it's CIN or CIMP. Clin Cancer Res, 14, 5939-40.   DOI
38 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.   DOI
39 Kawazoe Y, Naka T, Fujimoto M, et al (2001). Signal transducer and activator of transcription (STAT)-induced STAT inhibitor 1 (SSI-1)/suppressor of cytokine signaling 1 (SOCS-1) inhibits insulin signal transduction pathway through modulating insulin receptor substrate 1 (IRS-1) phosphorylation. J Exp Med, 193, 263-9.   DOI   ScienceOn
40 Kishimoto T, Kikutani H (2001). Knocking the SOCS off a tumor suppressor. Nature Genetics, 28, 4-5 .
41 Li HY, Zhang Y, Cai JH, Bian HL (2013). MicroRNA-451 inhibits growth of human colorectal carcinoma cells via downregulation of Pi3k/Akt pathway. Asian Pac J Cancer Prev, 14, 3631-4.   DOI
42 Komazaki T, Nagai H, Emi M, et al (2004). Hypermethylationassociated inactivation of the SOCS-1gene, a JAK/STAT inhibitor, in human pancreatic cancers. Jpn J Clin Oncol, 34, 191-4.   DOI
43 Lin SY, Yeh KT, Chen WT, et al (2004). Promoter CpG methylation of tumor suppressor genes in colorectal cancer and its relationship to clinical features. Oncol Rep, 11, 341-8.
44 Lee DW, Han SW, Lee HJ, et al (2013). Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy. Br J Cancer, 108, 1978-84.   DOI
45 Liao X, Lochhead P, Nishihara R, et al (2012). Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med, 367, 1596-06.   DOI
46 Melzner I, Bucur AJ, Bruderlein S, et al (2005). Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood, 105, 2535-42.   DOI
47 Morikawa T, Kuchiba A, Liao X, et al (2012). Tumor TP53 expression status, body mass index and prognosis in colorectal cancer. Int J Cancer, 131, 1169-78.   DOI
48 Nagai H, Naka T, Terada Y, et al (2003) Hypermethylation associated with inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human hepatoblastomas. J Hum Genet. 48, 65-9.   DOI
49 Nagai H, Naka T, Terada Y, et al (2003). Hypermethylation associated with inactivation of the SOCS-1gene, a JAK/STAT inhibitor, in human hepatoblastomas. J Hum Genet, 48, 65-9.   DOI
50 Ogino S, Nosho K, Irahara N, et al (2009). A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases. Clin Cancer Res, 15, 4431-38.   DOI
51 Ogino S, Nosho K, Kirkner GJ, et al (2009). CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut, 58, 90-96.   DOI